Related Experiment Video
Updated: Jan 22, 2026
06:51
Techniques to Induce and Quantify Cellular Senescence
Published on: May 1, 2017
34.9K
Cellular Senescence in Heart Failure: A Review.
Kamil Krauz1, Katarzyna Czarzasta1, Mikołaj Bugajewski1
1Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland.
Journal of Cellular Physiology
|January 21, 2026
Summary
Cellular senescence contributes to heart failure (HF) development and progression. Targeting senescent cells and related plasma proteins offers potential therapeutic strategies for improving HF outcomes.
Area of Science:
- Cardiology
- Gerontology
- Cell Biology
Background:
- Heart failure (HF) is a growing global health concern with limited treatment options.
- Aging is a major risk factor for HF, and cellular senescence is increasingly implicated in its pathogenesis.
- The precise role of cellular senescence in HF is complex and cell-type dependent.
Purpose of the Study:
- To review the intricate relationship between cellular senescence and heart failure.
- To explore the potential of senescent cell markers in plasma as biomarkers and prognostic indicators for HF.
- To summarize current and emerging senescence-targeting therapeutics for HF.
Main Methods:
- Comprehensive literature review of studies on cellular senescence and heart failure.
- Analysis of research on plasma proteins associated with cellular senescence in HF patients.
- Evaluation of therapeutic strategies targeting cellular senescence in the context of HF.
Main Results:
- Cellular senescence, a state of irreversible cell cycle arrest, is a significant contributor to HF pathogenesis.
- Plasma proteins linked to senescence show promise as biomarkers and prognostic factors for HF.
- Targeting senescent cells presents a potential therapeutic avenue for HF treatment.
Conclusions:
- Cellular senescence plays a multifaceted role in the development and progression of heart failure.
- Further research into senescence-associated plasma proteins could refine HF diagnosis and prognosis.
- Senolytics and other senescence-targeting therapies warrant investigation for HF management.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
783
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
783
01:17Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
01:27Heart Failure I: Introduction
723
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
723
01:22Heart Failure VI: Adjunct Therapies
277
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
277
01:22Heart Failure Drugs: Diuretics
824
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
824
01:30Heart Failure V: Medical Management
227
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227